- Home
- OCGN vs DSGN Comparison
OCGN vs DSGN Comparison
Compare OCGN & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCGN
- DSGN
- Stock Information
- Founded
- OCGN 2013
- DSGN 2017
- Country
- OCGN United States
- DSGN United States
- Employees
- OCGN N/A
- DSGN N/A
- Industry
- OCGN Biotechnology: Biological Products (No Diagnostic Substances)
- DSGN Biotechnology: Pharmaceutical Preparations
- Sector
- OCGN Health Care
- DSGN Health Care
- Exchange
- OCGN Nasdaq
- DSGN Nasdaq
- Market Cap
- OCGN 278.3M
- DSGN 208.9M
- IPO Year
- OCGN N/A
- DSGN 2021
- Fundamental
- Price
- OCGN $0.92
- DSGN $3.39
- Analyst Decision
- OCGN Strong Buy
- DSGN Hold
- Analyst Count
- OCGN 3
- DSGN 1
- Target Price
- OCGN $6.00
- DSGN $4.00
- AVG Volume (30 Days)
- OCGN 8.5M
- DSGN 89.5K
- Earning Date
- OCGN 08-07-2025
- DSGN 08-04-2025
- Dividend Yield
- OCGN N/A
- DSGN N/A
- EPS Growth
- OCGN N/A
- DSGN N/A
- EPS
- OCGN N/A
- DSGN N/A
- Revenue
- OCGN $4,522,000.00
- DSGN N/A
- Revenue This Year
- OCGN N/A
- DSGN N/A
- Revenue Next Year
- OCGN N/A
- DSGN N/A
- P/E Ratio
- OCGN N/A
- DSGN N/A
- Revenue Growth
- OCGN N/A
- DSGN N/A
- 52 Week Low
- OCGN $0.52
- DSGN $2.60
- 52 Week High
- OCGN $1.98
- DSGN $7.77
- Technical
- Relative Strength Index (RSI)
- OCGN 55.00
- DSGN 48.40
- Support Level
- OCGN $0.95
- DSGN $3.65
- Resistance Level
- OCGN $1.15
- DSGN $4.21
- Average True Range (ATR)
- OCGN 0.11
- DSGN 0.23
- MACD
- OCGN -0.02
- DSGN -0.00
- Stochastic Oscillator
- OCGN 22.62
- DSGN 23.81
About OCGN Ocugen Inc.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.